TCM
TARS icon

Tang Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Tang Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.4M Hold
1,188,624
– – 4.23% 12
2025
Q4 		$97.3M Sell
1,188,624
-1,266,173
-52% -$94.5M 4.81% 6
2025
Q3 		$146M Hold
2,454,797
– – 5.62% 1
2025
Q2 		$99.4M Hold
2,454,797
– – 5.03% 2
2025
Q1 		$126M Buy
2,454,797
+200,000
+9% +$9.89M 6.98% 1
2024
Q4 		$125M Hold
2,254,797
– – 8.26% 1
2024
Q3 		$74.2M Hold
2,254,797
– – 5.3% 2
2024
Q2 		$61.3M Hold
2,254,797
– – 6.24% 1
2024
Q1 		$82M Buy
2,254,797
+50,000
+2% +$1.47M 8.53% 1
2023
Q4 		$44.6M Buy
2,204,797
+64,211
+3% +$1.07M 4.13% 3
2023
Q3 		$38M Buy
2,140,586
+361,428
+20% +$6.4M 5.37% 1
2023
Q2 		$32.1M Sell
1,779,158
-255,000
-13% -$4.05M 4.73% 2
2023
Q1 		$25.6M Buy
2,034,158
+32,573
+2% +$476K 3.81% 5
2022
Q4 		$29.3M Sell
2,001,585
-88,271
-4% -$1.46M 4.26% 4
2022
Q3 		$35.8M Buy
2,089,856
+5,486
+0.3% +$87.1K 4.39% 4
2022
Q2 		$30.4M Buy
2,084,370
+1,784,370
+595% +$26.8M 4.62% 7
2022
Q1 		$5.05M Buy
+300,000
New +$5.57M 1.01% 29

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tang Capital Management's TARS Position: Q1 2026 in Review

Tang Capital Management held its Tarsus Pharmaceuticals (TARS) position steady in Q1 2026 at 1,188,624 shares worth $83.4M. The position accounts for 4.23% of the portfolio, ranked #12.

Tang Capital Management first reported a position in TARS in Q1 2022 and has held it in 17 quarters since. The position peaked at $146M in Q3 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Tang Capital Management held 1,188,624 shares of Tarsus Pharmaceuticals worth $83.4M as of Q1 2026.
  • Tang Capital Management left its Tarsus Pharmaceuticals share count unchanged in Q1 2026.
  • Tarsus Pharmaceuticals made up 4.23% of Tang Capital Management's portfolio in Q1 2026, its #12 holding.
  • Tang Capital Management first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Tang Capital Management's Tarsus Pharmaceuticals position peaked at $146M in Q3 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.